Viking Therapeutics stock jumped higher last year because it looks like a dual GLP-1/GIP agonist it's developing could ...

Viking is pursuing VK2809, an experimental treatment for metabolic dysfunction-associated steatohepatitis (MASH), outside VK2735. A Phase 2b VOYAGE study showed that VK2809 dramatically lowers ...

Nearly a year ago, Viking Therapeutics (NASDAQ ... The injectable version of the candidate, tentatively named VK2735, reduced obesity patients' weight by 14.7% after 13 weeks in a relatively ...

Citi analyst David Lebowitz initiated coverage of Viking Therapeutics (VKTX) with a Neutral rating and $38 price target Viking’s VK2735 is an “intriguing potential blockbuster,” with its GLP ...

The excitement surrounding Viking Therapeutics (NASDAQ ... company would acquire it for its promising GLP-1 treatment, VK2735 -- but that doesn't appear to be happening. And with a growing ...

Viking is pursuing VK2809, an experimental treatment for metabolic dysfunction-associated steatohepatitis (MASH), outside VK2735. A Phase 2b VOYAGE study showed that VK2809 dramatically lowers liver ...

Raymond James analyst Steven Seedhouse raised the firm’s price target on Viking Therapeutics (VKTX ... The firm notes that the two Phase 3 subQ VK2735 studies in obese and obese+T2DM patients ...

2024 was an exceptionally busy year for Viking. During the year, the company reported successful results from four different studies across our pipeline. These include: the announcement of positive ...